Show simple item record

dc.contributor.authorSzwedo, Aleksandra A
dc.contributor.authorDalen, Ingvild
dc.contributor.authorPedersen, Kenn Freddy
dc.contributor.authorCamacho, Marta
dc.contributor.authorBäckström, David
dc.contributor.authorForsgren, Lars
dc.contributor.authorTzoulis, Charalampos
dc.contributor.authorWinder-Rhodes, Sophie
dc.contributor.authorHudson, Gavin
dc.contributor.authorLiu, Ganqiang
dc.contributor.authorScherzer, Clemens R
dc.contributor.authorLawson, Rachael A
dc.contributor.authorYarnall, Alison J
dc.contributor.authorWilliams-Gray, Caroline H
dc.contributor.authorMacleod, Angus D
dc.contributor.authorCounsell, Carl E
dc.contributor.authorTysnes, Ole-Bjørn
dc.contributor.authorAlves, Guido
dc.contributor.authorMaple-Grødem, Jodi
dc.contributor.authorParkinson's Incidence Cohorts Collaboration
dc.date.accessioned2022-02-07T09:59:01Z
dc.date.available2022-02-07T09:59:01Z
dc.date.issued2022-05
dc.identifier.citationSzwedo , A A , Dalen , I , Pedersen , K F , Camacho , M , Bäckström , D , Forsgren , L , Tzoulis , C , Winder-Rhodes , S , Hudson , G , Liu , G , Scherzer , C R , Lawson , R A , Yarnall , A J , Williams-Gray , C H , Macleod , A D , Counsell , C E , Tysnes , O-B , Alves , G , Maple-Grødem , J & Parkinson's Incidence Cohorts Collaboration 2022 , ' GBA and APOE Impact Cognitive Decline in Parkinson's Disease : A 10-Year Population-Based Study ' , Movement Disorders , vol. 37 , no. 5 , pp. 1016-1027 . https://doi.org/10.1002/mds.28932en
dc.identifier.issn0885-3185
dc.identifier.otherPURE: 211980789
dc.identifier.otherPURE UUID: b78fe10d-6635-4082-ac0f-88951ef29e0e
dc.identifier.otherPubMed: 35106798
dc.identifier.otherPubMed: 35106798
dc.identifier.otherWOS: 000749610800001
dc.identifier.otherScopus: 85128723530
dc.identifier.urihttps://hdl.handle.net/2164/18036
dc.descriptionAcknowledgments: We would like to thank all participants, study personnel from each study, and funders of individual studies and of PICC. We would like to thank Artur Wozniak and Adrian Martin from the University of Aberdeen, Data Management Department, for help in developing the PICC database. We acknowledge the contributions of members of the individual study groups as detailed below. Members of PICC Steering Group: Dr. Angus D. Macleod, Dr. Carl E. Counsell (Chair), University of Aberdeen, UK; Prof. Ole-Bjørn Tysnes, University of Bergen, Norway; Marta Camacho, Dr. Caroline WilliamsGray, University of Cambridge, UK; Dr. Rachael A. Lawson, Newcastle University, UK; Dr. Jodi Maple-Grødem, Prof. Guido Alves, Stavanger University Hospital, Norway; Prof. Lars Forgren, Umeå University, Sweden. CamPaIGN study: Roger A. Barker, Thomas Foltynie, Sarah L. Mason, Caroline H. Williams-Gray. ICICLE-PD Study: David Burn, Lynn Rochester, Alison J. Yarnall, Rachael A. Lawson, Gordon W. Duncan, Tien K. Khoo. NYPUM Study: Lars Forsgren, Jan Linder, Mona Edström, Jörgen Andersson, Linda Eriksson, David Bäckström, Gun-Marie Hariz, Magdalena Domellöf. ParkWest Study: ParkWest Principal investigators: Guido Alves (Norwegian Centre for Movement Disorders, Stavanger University Hospital) and Ole-Bjørn Tysnes (Haukeland University Hospital). Study personnel: Michaela Dreetz Gjerstad, Kenn Freddy Pedersen, Elin Bjelland Forsaa, Veslemøy Hamre Frantzen, Anita Laugaland, Jodi MapleGrødem, Johannes Lange, Karen Simonsen, Eldbjørg Fiske and Ingvild Dalen (Stavanger University Hospital); Bernd Müller, Geir Olve Skeie and Marit Renså (Haukeland University Hospital); Wenche Telstad, Aliaksei Labusau and Jane Kastet (Førde Hospital); Ineke HogenEsch, Marianne Kjerandsen and Liv Kari Håland (Haugesund Hospital); Karen Herlofson, Solgunn Ongre, and Siri Bruun (Sørlandet Hospital Arendal). PICNICS study: Roger A. Barker, Marta Camacho, Gemma Cummins, Jonathan R. Evans, David P. Breen, Ruwani S. Wijeyekoon, Caroline H. Williams-Gray. PINE Study: Medical: Carl E. Counsell, Kate S. M. Taylor, Robert Caslake, Angus D. Macleod, David J. M. McGhee, Diane Swallow; Research nurse/assistant: Joanne Gordon, Clare Harris, Ann Hayman, Nicola Johannesson, Hazel Forbes; Data management: Valerie Angus, Alasdair Finlayson, David Dawson, Katie Wilde, David Ritchie, Artur Wozniak; Statisticians: Neil Scott, Shona Fielding; Radiology: Prof. Alison Murray; Pathology: Ishbel Gall, Dr. James MacKenzie, Prof. Colin Smith; Secretarial: Aileen Sylvester, Susan Mitchell, Pam Rebecca, Ann Christie, and Diane McCosh. Funding agencies: This work was supported by the Research Council of Norway (287842). The CamPaIGN study has received funding from the Wellcome Trust, the Medical Research Council, the Patrick Berthoud Trust, and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The ICICLE-PD study was funded by Parkinson’s UK (J-0802, G-1301, G-1507) and supported by the Lockhart Parkinson’s Disease Research Fund, National Institute for Health Research (NIHR) Newcastle Biomedical Research Unit and Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The NYPUM study was supported by grants from the Swedish Medical Research Council, Erling-Persson Foundation, the Swedish Brain Foundation (Hjärnfonden), Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Swedish Parkinson Research Foundation, Kempe Foundation, Swedish PD Association, the European Research Council, and the Knut and Alice Wallenberg Foundation. The Norwegian ParkWest study has received funding from the Research Council of Norway (177966), the Western Norway Regional Health Authority (911218), the Norwegian Parkinson’s Research Foundation, and Rebergs Legacy. The PICNICS study was funded by the Cure Parkinson’s Trust, the Van Geest Foundation, the Medical Research Council, Parkinson’s UK, and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The PINE study was funded by Parkinson’s UK (grant numbers G0502, G0914, and G1302), the Scottish Chief Scientist Office (CAF/12/05, PCL/17/10), Academy of Medical Sciences, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, and SPRING. The PICC collaboration has been supported by The Chief Scientist Office of the Scottish Government (PCL/17/10), the Academy of Medical Sciences, Parkinson’s UK (initial collaborator meeting) and the Norwegian Association for Public Health. C.R.S.’s work was supported by NIH grants NINDS/NIA R01NS115144, U01NS095736, U01NS100603, and the American Parkinson Disease Association Center for Advanced Parkinson Research. This research was funded in whole, or in part by the UKRI Medical Research Council [MR/R007446/1]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.en
dc.format.extent12
dc.language.isoeng
dc.relation.ispartofMovement Disordersen
dc.rights© 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. https://creativecommons.org/licenses/by/4.0/en
dc.subjectParkinson diseaseen
dc.subjectdementiaen
dc.subjectcognitive declineen
dc.subjectAPOEen
dc.subjectGBAen
dc.subjectParkinson's diseaseen
dc.subjectApolipoproteins E/geneticsen
dc.subjectMutation/geneticsen
dc.subjectHumansen
dc.subjectDementia/geneticsen
dc.subjectApolipoprotein E4/geneticsen
dc.subjectGlucosylceramidase/geneticsen
dc.subjectCognitive Dysfunction/geneticsen
dc.subjectParkinson Disease/complicationsen
dc.subjectMINI-MENTAL-STATEen
dc.subjectDEMENTIAen
dc.subjectSUSCEPTIBILITYen
dc.subjectRISKen
dc.subjectGLUCOCEREBROSIDASE MUTATIONSen
dc.subjectPOLYMORPHISMSen
dc.subjectMOTORen
dc.subjectSCALEen
dc.subjectASSOCIATIONen
dc.subjectONSETen
dc.subjectR Medicineen
dc.subjectClinical Neurologyen
dc.subjectNeurologyen
dc.subjectParkinson's UKen
dc.subjectG0502en
dc.subjectG0914en
dc.subjectG1302en
dc.subjectMedical Research Council (MRC)en
dc.subjectMR/R007446/1en
dc.subjectChief Scientist Office (CSO)en
dc.subjectCAF/12/05en
dc.subjectPCL/17/10en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subjectBRC-1215-20014en
dc.subjectWellcome Trusten
dc.subject.lccRen
dc.titleGBA and APOE Impact Cognitive Decline in Parkinson's Disease : A 10-Year Population-Based Studyen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medicine, Medical Sciences & Nutritionen
dc.contributor.institutionUniversity of Aberdeen.Data Safe Havenen
dc.contributor.institutionUniversity of Aberdeen.Chronic Disease Research Groupen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1002/mds.28932
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85128723530&partnerID=8YFLogxKen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record